A health-intelligence giant that helps drugmakers run clinical trials, sell their medicines, and make sense of huge piles of healthcare data—drawing on a trove covering roughly nine in ten of the world's pharmaceuticals. It was born in 2016 when Quintiles, the contract-research firm founded by a statistics professor in 1982, merged with IMS Health, a market-data company from 1954. Its name blends letters from both: the "I" from IMS and "Q" from Quintiles, plus "VIA" for the road ahead.
IQVIA Inc. issues €950M of 4.625% senior notes due 2033
On June 11, 2026, IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of €950,000,000 in gross proceeds of 4.625% senior notes due 2033.
Show detailsHide details
The notes were issued under an Indenture dated June 11, 2026, with U.S. Bank Trust Company, National Association as trustee and certain IQVIA subsidiaries as guarantors.
Net proceeds will be used to refinance certain existing indebtedness of the Issuer and to pay fees and expenses related to the offering.
The notes are unsecured, mature on June 15, 2033, and bear interest at 4.625% per year, payable semi-annually on June 15 and December 15, beginning December 15, 2026.
The Issuer may redeem the notes prior to maturity, subject to a make-whole premium before June 15, 2029, and thereafter at a declining premium from 2.313% to 0.000%.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits
IQVIA subsidiary prices €950M senior notes due 2033 at 4.625%
On June 4, 2026, IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €950,000,000 in senior notes due 2033.
Show detailsHide details
The notes bear interest at 4.625% per annum, payable semi-annually on June 15 and December 15, beginning December 15, 2026.
The notes mature on June 15, 2033, and the offering is expected to close on or about June 11, 2026, subject to customary closing conditions.
Proceeds will be used to refinance certain existing indebtedness of the issuer and to pay fees and expenses related to the offering.
The notes are being offered only to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
8.01 Other Events · 9.01 Financial Statements and Exhibits
IQVIA subsidiary to offer €950M senior notes due 2033 to refinance debt
On June 3, 2026, IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., intends to raise €950,000,000 through an offering of senior notes due 2033.
Show detailsHide details
The proceeds will be used to refinance certain existing indebtedness of the issuer and to pay fees and expenses related to the offering.
The offering is subject to market and other customary conditions and is not registered under the Securities Act; notes will be offered to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
The press release was filed as Exhibit 99.1 to the Form 8-K, which was filed under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
The report was signed by Eric M. Sherbet, Executive Vice President, General Counsel, and Secretary of IQVIA Holdings Inc.
8.01 Other Events · 9.01 Financial Statements and Exhibits
IQVIA board authorizes additional $2B share repurchase, total remaining $3.217B
On May 7, 2026, IQVIA Holdings Inc. announced its board authorized an additional $2,000 million share repurchase under its existing equity repurchase program.
Show detailsHide details
The total remaining authorization under the Repurchase Program is now $3,217 million.
The Repurchase Program has no expiration date and does not obligate IQVIA to repurchase any specific amount.
Repurchases may be made in open market, block trades, or privately negotiated transactions, and may be modified, suspended, or discontinued at any time.
The announcement was made via a press release dated May 7, 2026, filed as Exhibit 99.1 to the Form 8-K.
8.01 Other Events · 9.01 Financial Statements and Exhibits
IQVIA stockholders approve 2026 Incentive and Stock Award Plan at annual meeting
The 2026 Plan authorizes performance- and time-based equity awards, including stock options, stock appreciation rights, restricted stock, and restricted stock units.
Show detailsHide details
At the April 23, 2026 Annual Meeting, stockholders approved the 2026 Incentive and Stock Award Plan, which replaces the 2017 plan and became effective immediately.
All nine director nominees were elected, including Ari Bousbib, Carol J. Burt, and John G. Danhakl, with votes ranging from about 135.8 million to 147.9 million for each.
The advisory say-on-pay proposal for 2025 executive compensation passed with about 118.4 million votes for and 29.4 million against.
Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for 2026 and rejected a proposal to separate the Chairman and CEO roles.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits